News

Quattroflow™ Launches EZ-Set Pump Chamber Replacing System for Single-Use Pumps

Quattroflow™, part of PSG®, a Dover company and a leading brand of positive displacement quaternary diaphragm pumps, is pleased to announce the launch of the EZ-Set Pump Chamber Replacing System for its Single-Use pumps. With EZ-Set, users can replace a Single-Use pump chamber in 30 seconds by hand without the use of special tools or torque wrenches. It’s quick, it’s easy, and it’s safe. The comfortable handgrip design of the EZ-Set makes replacing the pump chamber so easy you can…

Selexis Announces Commercial License Agreement with Takeda for the Development of Fusion Proteins

Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today that it has entered a commercial license agreement (CLA) that provides Takeda Pharmaceutical Company Limited [TSE:4502], (“Takeda”) with access to high-performance research cell banks (RCBs) developed using the Selexis SUREtechnology Platform™. Takeda is leveraging Selexis’ mammalian cell line-based protein expression platform to develop recombinant fusion proteins. “Successfully developing a high-performance cell line expressing Takeda’s fusion proteins validates the strength of our…

Sartorius Stedim Biotech introduces Sartobind® Cassettes

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, has expanded its range of single-use membrane chromatography solutions with Sartobind® Cassettes. This convenient, pod-like modular system has been developed for commercial applications in both capture and polishing. New Sartobind® cassettes offer the same flow path, bed heights (4 and 8 mm) and void volume ratios as Sartobind® capsules, and are compatible with Q, S, STIC PA and phenyl ligands. The new design goes beyond the previous 5…

KBI Biopharma Acquires Alliance Protein Laboratories, Expands Biophysical Characterization Capabilities

KBI Biopharma, Inc. (KBI) has agreed to acquire the assets of San Diego-based Alliance Protein Laboratories (Alliance), a leading analytical services company specializing in biophysical characterization of biopharmaceuticals. Founded in 1998, Alliance is well known and highly regarded around the world for its expertise in characterization of therapeutic proteins, peptides, nucleic acids and vaccines. Recognized as the foremost expert in analytical ultracentrifugation (AUC), an essential technology for determining physical stability, association state, molecular weight and quantitative characterization of protein aggregates,…

JSR Life Sciences Acquires Cell Line Developer Selexis SA, Integrates With KBI Biopharma, Inc.

JSR Life Sciences (JLS) announced today that JSR Corporation has agreed to acquire Selexis SA, a pioneering life sciences company and global leader in mammalian (suspension-adapted CHO-K1) cell-line generation technologies. Once completed, this transaction will mark the second major biotechnology addition to the JSR group of companies following JSR Corporation’s acquisition of KBI Biopharma in 2015. Selexis will be integrated within KBI Biopharma’s operations to create the most robust and fastest “Gene to GMP” service offering in the biopharmaceutical industry.…

Rentschler Biotechnologie and Rentschler Fill Solutions Announce Strategic Partnership for One-Stop Solutions with New State-of-the-Art Fill and Finish Facilities

Rentschler Biotechnologie GmbH, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Rentschler Fill Solutions GmbH, an independent specialist for aseptic fill and finish services, today announced a strategic partnership to provide new state-of-the-art fill and finish facilities and one-stop solutions for biopharmaceutical products to meet the needs of Rentschler Biotechnologie’s clients. Under the terms of the agreement, Rentschler Fill Solutions will prospectively serve as the exclusive partner for the fill and finish services of Rentschler Biotechnologie’s manufacturing…

Eppendorf Introduces the New BioFlo® 120 Bioprocess Control Station

Leading life science company Eppendorf introduces the BioFlo 120, their latest bench scale fermentor/bioreactor system for research and development. This flexible instrument is capable of microbial fermentation as well as mammalian cell culture applications with a single platform. It features an extensive range of glass and BioBLU® Single-Use Vessel options (250 mL – 40 L). Universal connections for digital Mettler Toledo® ISM and analog sensors make it easy to monitor a variety of critical process parameters. “We know that in…

Sartorius Stedim Biotech Launches ambr® 15 Bioreactor System with Nova BioProfile® FLEX2 Integration

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, announced that the ambr® 15 automated micro bioreactor system combined with a Nova Biomedical (Nova) BioProfile® FLEX2 automated cell culture analyzer is on show for the first time at the Cell Line Development & Engineering Conference in San Diego, California. This newly integrated system, which is a first from SSB and Nova’s successful collaboration, enables rapid at-line sample collection and analysis of massive quantities of key cell culture…

Vetter and Microdermics Enter into a Strategic Cooperation Agreement to Develop Innovative Microneedle Drug Delivery Systems

Vetter, a leading and innovative provider of aseptic prefilled drug delivery systems and Microdermics Inc., a Vancouver-based medical device company developing a novel hollow, metal microneedle drug and vaccine delivery system, today announced that they have entered into a strategic cooperation agreement. The market in novel alternatives to needle injections is forecasted to grow rapidly, reaching in excess of 480 million units by 2030 (Roots Analysis report). Microneedles are a novel technology that can offer promising advantages as an alternative…

Lonza Acquires Cell and Gene Contract Manufacturer PharmaCell

On 3 May 2017, Lonza successfully completed the acquisition of PharmaCell B.V., one of the most-respected cell and gene contract manufacturers in Europe with employees in Maastricht and Geleen (NL). In 2016 PharmaCell had sales of EUR 11 million. PharmaCell was primarily selected due to its core expertise in autologous cell and gene therapy manufacturing, which includes experience with two commercial Advanced Therapy Medicinal Products (ATMPs)-licensed products. Autologous therapies use a patient’s own cells. “PharmaCell’s position in the market complements…